PURPOSE: The aim of this study is to test the psychometric properties and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) inpatient satisfaction with care questionnaire 32 (IN-PATSAT32) for evaluating Chinese cancer patients and to analyze the influence of age, educational level, diagnostic time, and tumor stage on patient satisfaction. METHODS: Three hundred two cancer inpatients in Tianjin Cancer Institution and Hospital from June 2013 to December 2013 were recruited for this study. All participants self-administered the EORTC IN-PATSAT32 and EORTC quality of life questionnaire-core 30 (QLQ-C30). Psychometric evaluation of the validity, reliability, acceptability, as well as the influence of age, educational level, diagnostic time, and tumor stage on patient satisfaction, was conducted. RESULTS: A favorable internal consistency reliability was confirmed, as the Cronbach's α coefficients were >0.80 for all scales in the EORTC IN-PATSAT32, ranging from 0.849 to 0.944. Multi-trait scaling analysis showed that all item-scale correlation coefficients met the standard of convergent validity, and 79.3 % met the standard of discriminant validity. Weak correlations were found between the scales and single items of the EORTC IN-PATSAT32 and EORTC QLQ-C30, proving the validity of EORTC IN-PATSAT32. None of the EORTC IN-PATSAT32 scales were able to discriminate between patients across age categories, while significant influences of educational level on doctors' and nurses' conduct, as well as influences of diagnostic time and tumor stage on nurses' conduct, and information provision scales were discovered. The questionnaire was easily understood with a satisfactory acceptability. CONCLUSIONS: The EORTC IN-PATSAT32 appears to be a reliable, valid, and acceptable instrument to use on cancer patients and is appropriate for measuring the patient satisfaction of Chinese patients.
PURPOSE: The aim of this study is to test the psychometric properties and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) inpatient satisfaction with care questionnaire 32 (IN-PATSAT32) for evaluating Chinese cancerpatients and to analyze the influence of age, educational level, diagnostic time, and tumor stage on patient satisfaction. METHODS: Three hundred two cancer inpatients in Tianjin Cancer Institution and Hospital from June 2013 to December 2013 were recruited for this study. All participants self-administered the EORTC IN-PATSAT32 and EORTC quality of life questionnaire-core 30 (QLQ-C30). Psychometric evaluation of the validity, reliability, acceptability, as well as the influence of age, educational level, diagnostic time, and tumor stage on patient satisfaction, was conducted. RESULTS: A favorable internal consistency reliability was confirmed, as the Cronbach's α coefficients were >0.80 for all scales in the EORTC IN-PATSAT32, ranging from 0.849 to 0.944. Multi-trait scaling analysis showed that all item-scale correlation coefficients met the standard of convergent validity, and 79.3 % met the standard of discriminant validity. Weak correlations were found between the scales and single items of the EORTC IN-PATSAT32 and EORTC QLQ-C30, proving the validity of EORTC IN-PATSAT32. None of the EORTC IN-PATSAT32 scales were able to discriminate between patients across age categories, while significant influences of educational level on doctors' and nurses' conduct, as well as influences of diagnostic time and tumor stage on nurses' conduct, and information provision scales were discovered. The questionnaire was easily understood with a satisfactory acceptability. CONCLUSIONS: The EORTC IN-PATSAT32 appears to be a reliable, valid, and acceptable instrument to use on cancerpatients and is appropriate for measuring the patient satisfaction of Chinese patients.
Authors: A Brédart; A Bottomley; J M Blazeby; T Conroy; C Coens; S D'Haese; Wei-Chu Chie; E Hammerlid; J I Arraras; F Efficace; C Rodary; S Schraub; M Costantini; A Costantini; F Joly; O Sezer; D Razavi; M Mehlitz; M Bielska-Lasota; N K Aaronson Journal: Eur J Cancer Date: 2005-09 Impact factor: 9.162
Authors: Rollon Poinsot; A Altmeyer; T Conroy; A Savignoni; B Asselain; I Léonard; E Marx; M Cosquer; M Sévellec; J Gledhill; C Rodary; M Mercier; P Dickès; M Fabbro; P Antoine; S Guerif; S Schraub; S Dolbeault; A Brédart Journal: Bull Cancer Date: 2006-03-01 Impact factor: 1.276
Authors: A Brédart; C Coens; N Aaronson; W-C Chie; F Efficace; T Conroy; J M Blazeby; E Hammerlid; M Costantini; F Joly; S Schraub; O Sezer; J I Arraras; C Rodary; A Costantini; M Mehlitz; D Razavi; A Bottomley Journal: Eur J Cancer Date: 2006-12-06 Impact factor: 9.162
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: A Brédart; V Mignot; A Rousseau; S Dolbeault; N Beauloye; V Adam; C Elie; I Léonard; B Asselain; T Conroy Journal: Patient Educ Couns Date: 2004-08
Authors: Koen I Neijenhuijs; Femke Jansen; Neil K Aaronson; Anne Brédart; Mogens Groenvold; Bernhard Holzner; Caroline B Terwee; Pim Cuijpers; Irma M Verdonck-de Leeuw Journal: Support Care Cancer Date: 2018-05-07 Impact factor: 3.603